Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 3 study of sodium zirconium cyclosilicate in pediatric hyperkalemia
CTR20221841Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Mar 2023
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sodium zirconium cyclosilicate in hyperkalemia, sponsored by AstraZeneca. Started Mar 2023; status: active.
02
Drugs
sodium zirconium cyclosilicate
03
Conditions
hyperkalemia
Beyond the preview
Go deeper on CTR20221841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221841.